Introduction Origins of Medicinal Chemistry |
|
1 | (10) |
|
Part I Principles of Drug Discovery |
|
11 | (234) |
|
Overview Drug Design and Development: A Perspective |
|
|
12 | (12) |
|
|
|
24 | (13) |
|
|
Drug Design and Relationship of Functional Groups to Pharmacologic Activity |
|
|
37 | (31) |
|
|
|
Molecular Modeling and Drug Design |
|
|
68 | (18) |
|
|
Receptors and Drug Action |
|
|
86 | (14) |
|
|
|
Drug Design Through Enzyme Inhibition |
|
|
100 | (14) |
|
|
Peptide and Protein Drugs |
|
|
114 | (29) |
|
|
Physicochemical and Biopharmaceutical Properties of Drug Substances and Pharmacokinetics |
|
|
143 | (31) |
|
|
|
174 | (60) |
|
|
U.S. Drug Regulation: An Overview |
|
|
234 | (11) |
|
Part II Pharmacodynamic Agents |
|
245 | (19) |
|
Overview Drug Receptors: A Perspective |
|
|
246 | (18) |
|
Section 1 Drugs Affecting Neurotransmission |
|
264 | (93) |
|
Drugs Affecting Cholinergic Neurotransmission |
|
|
264 | (28) |
|
|
|
Drugs Affecting Adrenergic Neurotransmission |
|
|
292 | (23) |
|
|
Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission |
|
|
315 | (23) |
|
|
|
|
338 | (19) |
|
Section 2 Drugs Affecting Central Nervous System |
|
357 | (140) |
|
|
357 | (13) |
|
|
|
370 | (14) |
|
|
|
384 | (24) |
|
|
Psychotherapeutic Drugs: Antipsychotic and Anxiolytic Agents |
|
|
408 | (26) |
|
|
|
Hallucinogens, Stimulants, and Related Drugs of Abuse |
|
|
434 | (19) |
|
|
|
453 | (27) |
|
|
Drugs Used to Treat Neuromuscular Disorders: Antiparkinsonian and Spasmolytic Agents |
|
|
480 | (17) |
|
|
Section 3 Drugs Affecting the Cardiovascular System |
|
497 | (132) |
|
Cardiac Agents: Cardiac Glycosides, Antianginal, and Antiarrhythmic Drugs |
|
|
497 | (21) |
|
|
|
518 | (15) |
|
|
Angiotensin Converting Enzyme Inhibitors, Antagonists and Calcium Blockers |
|
|
533 | (29) |
|
|
Central and Peripheral Sympatholytics and Vasodilators |
|
|
562 | (18) |
|
|
Antihyperlipoproteinemics and Inhibitors of Cholesterol Biosynthesis |
|
|
580 | (24) |
|
|
Antithrombotics, Thrombolytics, Coagulants and Plasma Extenders |
|
|
604 | (25) |
|
Section 4 Drugs Affecting the Hormonal Systems |
|
629 | (122) |
|
Insulin and Oral Hypoglycemic Drugs |
|
|
629 | (24) |
|
|
|
653 | (32) |
|
|
|
|
Estrogen, Progestins and Androgens |
|
|
685 | (33) |
|
|
|
|
Thyroid Function and Thyroid Drugs |
|
|
718 | (21) |
|
|
|
739 | (12) |
|
Section 5 Drugs Affecting the Immune Systems |
|
751 | (68) |
|
Nonsteroidal Anti-Inflammatory Agents |
|
|
751 | (43) |
|
|
Antihistamines and Related Antiallergic and Antiulcer Agents |
|
|
794 | (25) |
|
Section 6 Chemotherapeutic Agents |
|
819 | (162) |
|
Antibiotics and Antimicrobial Agents |
|
|
819 | (48) |
|
|
|
867 | (24) |
|
|
|
891 | (13) |
|
|
|
|
904 | (20) |
|
|
Cancer and Cancer Chemotherapy |
|
|
924 | (28) |
|
|
|
Antiviral Agents and Protease Inhibitors |
|
|
952 | (29) |
|
Part III Recent Advances in Drug Discovery |
|
981 | (89) |
|
Pharmaceutical Biotechnology |
|
|
982 | (34) |
|
|
|
1016 | (36) |
|
|
Antisense Therapeutic Agents |
|
|
1052 | (7) |
|
|
Selective Estrogen Receptor Modulators |
|
|
1059 | (11) |
|
Appendices pKa Values for Some Drugs and Miscellaneous Organic Acids and Bases pH Values for Tissue Fluids |
|
1070 | |
|